Markus Möhler, MD, PhD
Avelumab (Bavencio) did not improve overall survival (OS) as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, according to topline results from the phase III JAVELIN Gastric 100 study.1
Grade ≥3 treatment-related AEs occurred in 9.2% of the avelumab group compared with 31.6% of the chemotherapy group.
- EMD Serono and Pfizer provide update on phase III JAVELIN GASTRIC 100 trial. Pfizer. Published November 8, 2019. https://bit.ly/36IzHpP. Accessed November 8, 2019.
- Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
... to read the full story